Province Wide Rounds is a collaboration between the UBC Division of Nephrology and BC Renal.
Dr. Navdeep Tangri, a physician and associate professor with the Department of Nephrology at the University of Manitoba, discusses the current practices, as well as benefits and harms, of managing hyperkalemia in patients with chronic kidney disease (CKD).
0:03:14 – Overview of Hyperkalemia
Dr. Tangri starts by defining hyperkalemia and how it disproportionately occurs in patients with kidney disease. He goes on to describe the how heart failure and renin-angiotensin-aldosterone system (RAAS) inhibitors are associated with the condition..
0:09:45 – Study on Hyperkalemia and RAAS Inhibitors
Dr. Tangri discusses his own research, looking at the impact of discontinuing the use of RAAS inhibitors after hyperkalemia. His team conducted a retrospective cohort study using administrative data from Manitoba. Over a three-year period following hyperkalemia events, there was a high rate of mortality among patients (largely cardiovascular-related deaths); discontinuation of RAAS inhibitors was associated with significantly higher chance of death. He also presents data on suboptimal and maximum doses. There is some benefit for dose reduction over discontinuation.
0:24:49 – Summary of Findings
He summarizes the key findings from the study and discusses limitations.
0:25:09 – Existing Treatment Options for Hyperkalemia
Dr. Tangri goes on to discuss current practices of treating hyperkalemia, highlighting the advantages and disadvantages of sodium polystyrene sulfonate (SPS) and loop diuretics.
0:30:06 – New Treatment Options for Hyperkalemia
He talks about new potassium binders, including SZC and Patiromer. Patiromer is a novel, non-absorbed potassium binder that has been found to safely and effectively lower potassium levels.
0:39:59 – Questions From the Audience
#KidneyCare #Hyperkalemia #Potassium
